Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis

Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old female who developed odynophagia and bloody diarrhea following treatment with ocrelizu...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnes, Alex, Hofmann, Dirk, Hall, Lesley-Ann, Klebe, Sonja, Mountifield, Réme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079880/
https://www.ncbi.nlm.nih.gov/pubmed/33948072
http://dx.doi.org/10.20524/aog.2021.0582
Descripción
Sumario:Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old female who developed odynophagia and bloody diarrhea following treatment with ocrelizumab. This was characterized endoscopically by ulcerations in the esophagus and colon. The patient was treated with high-dose intravenous glucocorticoids with good clinical response.

Ejemplares similares